Rigorous, transparent and inconclusive: what Europe's first joint clinical assessment reveals about a framework trying to serve everyone.

On 30 April 2026, the Member State Coordination Group on Health Technology Assessment endorsed Europe's first joint clinical assessment (JCA) under Regulation (EU) 2021/2282, evaluating tovorafenib (Ojemda) for pediatric low-grade glioma harboring BRAF alterations. This perspective analyses the inaugural JCA report as a diagnostic of the European Health Technology Assessment framework under conditions of structural evidentiary constraint. The assessment revealed two structural points. First, between evidentiary rigor and feasibility: seven of eight predefined PICO (Population, Intervention, Comparator, Outcome) questions could not be answered comparatively, reflecting both the unavoidable limits of single-arm trial design in ultra-rare pediatric oncology and addressable failures in submission quality. Second, a temporal: the JCA is a one-time assessment, yet the report repeatedly identifies uncertainties that future evidence could reduce, with no regulatory mechanism to update the record. Our perspective further examines how comparator selection risks encoding access inequality as a scientific requirement, how the framework's legislative scope renders caregiver and family burden invisible to assessment, and how the absence of explicit certainty grading limits the actionability of JCA outputs for national payers. We suggest some improvements organized across three tiers: better use of existing mechanisms, guidance development within the current framework and legislative revision where structural change is required.